Get started
Author

Yuichi Koshiyama

Observed names: Koshiyama Y., Y., Koshiyama
ORCID: 0009-0006-1247-1215
Observed ORCID: 0009-0006-1247-1215
OpenAlex ID: A5082708281
Prevalence of pruritus in patients with chronic liver disease: A multicenter study
2017 · Satoshi Oeda, Hirokazu Takahashi, et al. · Hepatology Research · 64
PDF
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice
2024 · Atsushi Hiraoka, Toshifumi Tada, et al. · Hepatology Research · 20
PDF
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
2024 · Toshifumi Tada, Takashi Kumada, et al. · Alimentary Pharmacology & Therapeutics · 19
A machine learning algorithm for stratification of risk of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease
2024 · Naoki Shibata, Yasuhiro Morita, et al. · European Journal of Internal Medicine · 17
PDF
Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma
2024 · Makoto Chuma, Haruki Uojima, et al. · Hepatology International · 16
PDF
Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS
2017 · Tsunehiro Ochi, Takumi Kawaguchi, et al. · Scientific Reports · 13
PDF
Viral eradication reduces all‐cause mortality in patients with chronic hepatitis C virus infection who had received direct‐acting antiviral therapy
2024 · Toshifumi Tada, Masayuki Kurosaki, et al. · Liver International · 12
PDF
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study
2025 · Takeshi Hatanaka, Yutaka Yata, et al. · Liver International · 11
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma
2025 · Kazunari Tanaka, Kunihiko Tsuji, et al. · Liver Cancer · 8
Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression
2025 · Takashi Kumada, Hidenori Toyoda, et al. · Alimentary Pharmacology & Therapeutics · 7
Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
2025 · Tomomitsu Matono, Toshifumi Tada, et al. · Hepatology Research · 7
Impact of time‐of‐day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study
2025 · Atsushi Naganuma, Satoru Kakizaki, et al. · Hepatology Research · 7
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real‐World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
2026 · Tomomitsu Matono, Toshifumi Tada, et al. · Journal of Gastroenterology and Hepatology · 6
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child–Pugh Class B: A Real‐World Study
2026 · Hideko Ohama, Atsushi Hiraoka, et al. · Hepatology Research · 6
Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors
2025 · Tsukasa Yasuda, Takanori Ito, et al. · Digestive and Liver Disease · 6
PDF
Comparison of Surgical Resection and Radiofrequency Ablation for Early‐Stage HCC Patients With Child–Pugh Class B
2025 · Takeshi Hatanaka, Satoru Kakizaki, et al. · Journal of Gastroenterology and Hepatology · 5
The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient
2025 · Atsushi Hiraoka, Masatoshi Kudo, et al. · Oncology · 5
Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
2026 · Tomomitsu Matono, Toshifumi Tada, et al. · Liver International · 4
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma
2026 · Atsushi Hiraoka, Toshifumi Tada, et al. · Liver Cancer · 3
PDF
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis
2025 · Takeshi Hatanaka, Yutaka Yata, et al. · Hepatology Research · 3
Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinoma
2025 · Takeshi Hatanaka, Kei Shibuya, et al. · Hepatology Communications · 3
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma
2025 · Hideko Ohama, Atsushi Hiraoka, et al. · Journal of Gastroenterology · 3
Validation of a B‐mode ultrasonography scoring system for assessing liver steatosis: A comparison with MRI‐Derived proton density fat fraction
2025 · Toshifumi Tada, Takashi Kumada, et al. · Hepatology Research · 3
Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular Carcinoma
2025 · Hideko Ohama, Atsushi Hiraoka, et al. · Oncology · 2
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
2025 · Tomomitsu Matono, Toshifumi Tada, et al. · Hepatology Research · 2
Works count: 44
Citation count: 261
H-index: 8
I10-index: 8
Year
Topic
Type